These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Douwes JM; van Loon RL; Hoendermis ES; Vonk-Noordegraaf A; Roofthooft MT; Talsma MD; Hillege HL; Berger RM Eur Heart J; 2011 Dec; 32(24):3137-46. PubMed ID: 21893489 [TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700 [TBL] [Abstract][Full Text] [Related]
5. [Pediatric pulmonary hypertension and pulmonary arterial hypertension secondary to congenital heart diseases]. Olguntürk R Anadolu Kardiyol Derg; 2010 Aug; 10 Suppl 1():50-6. PubMed ID: 20819767 [TBL] [Abstract][Full Text] [Related]
6. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. van Loon RL; Roofthooft MT; Hillege HL; ten Harkel AD; van Osch-Gevers M; Delhaas T; Kapusta L; Strengers JL; Rammeloo L; Clur SA; Mulder BJ; Berger RM Circulation; 2011 Oct; 124(16):1755-64. PubMed ID: 21947294 [TBL] [Abstract][Full Text] [Related]
7. Assessment of endpoints in the pediatric population: congenital heart disease and idiopathic pulmonary arterial hypertension. Haworth SG; Beghetti M Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S35-41. PubMed ID: 20375663 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071 [TBL] [Abstract][Full Text] [Related]
9. Pulmonary arterial hypertension and women. De Marco T Cardiol Rev; 2006; 14(6):312-8. PubMed ID: 17053380 [TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893 [TBL] [Abstract][Full Text] [Related]
12. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. van Loon RL; Roofthooft MT; Delhaas T; van Osch-Gevers M; ten Harkel AD; Strengers JL; Backx A; Hillege HL; Berger RM Am J Cardiol; 2010 Jul; 106(1):117-24. PubMed ID: 20609658 [TBL] [Abstract][Full Text] [Related]
13. Management of dyspnea in advanced pulmonary arterial hypertension. Sajkov D; Petrovsky N; Palange P Curr Opin Support Palliat Care; 2010 Jun; 4(2):76-84. PubMed ID: 20407377 [TBL] [Abstract][Full Text] [Related]